
Kuros Biosciences AG (0RHR.L)
0RHR.L Stock Price Chart
Explore Kuros Biosciences AG interactive price chart. Choose custom timeframes to analyze 0RHR.L price movements and trends.
0RHR.L Company Profile
Discover essential business fundamentals and corporate details for Kuros Biosciences AG (0RHR.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
24 May 2023
Employees
122.00
Website
https://www.kuros.chCEO
Christopher T. Fair
Description
Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company's orthobiologics pipeline products include MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products comprise KUR-111, which has completed Phase 2b clinical trial for the treatment of tibial plateau fractures; and KUR-113, which completed Phase 2b clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase II trial for the treatment of spinal interbody fusion. The company's sealants pipeline products include Neuroseal EU and US, synthetic tissue sealant for the prevention of cerebrospinal fluid leakage following cranial or spinal surgery. It has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. The company is headquartered in Schlieren, Switzerland.
0RHR.L Financial Timeline
Browse a chronological timeline of Kuros Biosciences AG corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 9 Mar 2026
Upcoming earnings on 13 Aug 2025
Earnings released on 11 Mar 2025
EPS came in at -CHF 0.11, while revenue for the quarter reached CHF 43.71M, missing expectations by -3.51%.
Earnings released on 10 Oct 2024
EPS came in at -CHF 0.01, while revenue for the quarter reached CHF 31.84M, beating expectations by +6.15%.
Earnings released on 13 Mar 2024
EPS came in at -CHF 0.24, while revenue for the quarter reached CHF 20.70M, beating expectations by +10.68%.
Earnings released on 30 Jun 2023
EPS came in at -CHF 0.14, while revenue for the quarter reached CHF 12.87M, beating expectations by +36.87%.
Earnings released on 31 Dec 2022
EPS came in at -CHF 0.32, while revenue for the quarter reached CHF 7.56M, missing expectations by -14.09%.
Earnings released on 30 Jun 2022
EPS came in at -CHF 0.11, while revenue for the quarter reached CHF 10.43M, beating expectations by +10.91%.
Earnings released on 31 Dec 2021
EPS came in at -CHF 0.23, while revenue for the quarter reached CHF 4.73M, missing expectations by -33.39%.
Earnings released on 30 Jun 2021
EPS came in at -CHF 0.00, while revenue for the quarter reached CHF 9.09M, missing expectations by -0.15%.
Stock split effective on 11 Jun 2021
Shares were split 217:200, changing the number of shares outstanding and the price per share accordingly.
Earnings released on 31 Dec 2020
EPS came in at -CHF 0.21 surpassing the estimated -CHF 0.30 by +28.79%, while revenue for the quarter reached CHF 2.74M, beating expectations by +9.76%.
0RHR.L Stock Performance
Access detailed 0RHR.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.